Q2 2020 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$93M-56.7% YoY

Gross Profit

$57M60.6% margin

Operating Income

-$68M-73.3% margin

Net Income

-$55M-59.4% margin

EPS (Diluted)

$-0.74

QoQ Revenue Growth

-43.2%

Cash Flow

Operating Cash Flow

$30M

Free Cash Flow

$28M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$486M

Stockholders' Equity

$918M

Cash & Equivalents

$164M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$93M	$215M	-56.7%
Gross Profit	$57M	$165M	-65.7%
Operating Income	-$68M	-$6M	-1119.6%
Net Income	-$55M	-$4M	-1219.0%

Revenue Segments

Molecular Diagnostic Testing

$83M47%

Molecular Diagnostic Hereditary Cancer Testing

$40M23%

Molecular Diagnostic Prenatal Testing

$17M9%

Pharmaceutical And Clinical Services

$10M6%

Molecular Diagnostic Genesight Testing

$9M5%

Molecular Diagnostic Vectra Testing

$7M4%

Molecular Diagnostic Prolaris Testing

$5M3%

Molecular Diagnostic Other Testing

$4M2%

Molecular Diagnostic Endo Predict Testing

$2M1%